pta AK, et al., Shear NH, Hepatitis associated with terbinafine therapy: three case reports and a review of the literature, Clin Exp Dermatol, 1998;23:64–7.
nnet F, et al., A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997–1999, Clin Infect Dis, 2002;35:1231–7.
nez M, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, J Hepatol, 2006;44:S132–9.
rvin-Abad L, et al., Liver enzymes elevation after HAART in HIV-HCV co-infection, J Viral Hepat, 2005;12:429–34.
i AR, et al., Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus, AIDS Patient Care STDS, 2006;20:678–92.
n Brinker M, et al., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 2000;14:2895–902.
lkowski MS, Viral hepatitis and HIV coinfection, J Hepatol, 2008;48:353–67.
barga P, et al., Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients, J Infect Dis, 2007;196:670–6.
ah T, et al., Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual, J Infect Dis, 2008;197:932–3.
rtinez E, et al., Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy, AIDS, 2001;15:1261–8.
rtin AM, et al., Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts, AIDS, 2005;19:97–9.
114.Dieterich DT, et al., Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors, Clin Infect Dis, 2004;38(Suppl 2):S80–9.
nne I, et al., Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects, J Infect Dis, 2005;191:825–9.
rti C, et al., Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients, Drug Saf, 2007;30:1161–9.
Lazzari E, et al., Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts, HIV Med, 2008;9:221–6.
obel H, et al., Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count, HIV Med, 2008;9:14–8.
drano J, et al., Risk for immune-mediated liver reactions by nevirapine revisited, AIDS Rev, 2008;10:110–5.
Maat MM, et al., Case series of acute hepatitis in a non- selected group of HIV-infected patients on nevirapine- containing antiretroviral treatment, AIDS, 2003;17:2209–14.
llal S, et al., Association between presence of HLA- B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV- 1 reverse-transcriptase inhibitor abacavir, Lancet, 2002;359:727–32.
illips EJ, et al., HLA and drug-induced toxicity, Curr Opin Mol Ther, 2009;11:231–42.
hnson AA, et al., Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase, J Biol Chem, 2001;276:40847–57.
lkowski MS, et al., Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus, AIDS, 2005;19:585–92.
ler KD, et al., Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases, Ann Intern Med, 2000;133:192–6.
lkowski MS, et al., Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection, JAMA, 2000;283:74–80.
eti A, et al., Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus
infection, J Acquir Immune Defic Syndr, 2002;29:41–8.
lkowski MS, et al., Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir, AIDS, 2004;18:2277–84.
er CL, et al., Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus, Clin Infect Dis, 2002;34:1259–63.
130.Zucker SD, et al., Mechanism of indinavir-induced hyperbilirubinemia, Proc Natl Acad Sci U S A, 2001;98:12671–6.
aham DJ, Green L, Senior JR, Nourjah P, Troglitazone- induced liver failure: a case study, Am J Med, 2003;114:299–306.
an KA, et al., A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents, Arch Intern Med, 2003;163:728–34.
rcy TR, et al., Second-generation thiazolidinediones and hepatotoxicity, Ann Pharmacother, 2004;38:1419–23.
-Salman J, et al., Hepatocellular injury in a patient receiving rosiglitazone. A case report, Ann Intern Med, 2000;132:121–4.
rman LM, et al., Hepatic failure in a patient taking rosiglitazone, Ann Intern Med, 2000;132:118–21.
136.Farley-Hills E, et al., Fatal liver failure associated with pioglitazone, BMJ, 2004;329:429.
ase MP, et al., Pioglitazone-associated fulminant hepatic failure, Am J Gastroenterol, 2002;97:502–3.
truk V, et al., [Acute cholestatic hepatitis induced by glimepiride], Gastroenterol Clin Biol, 2000;24:1233–4.
139.Heurgue A, et al., [Glimepiride-induced cute cholestatic hepatitis], Ann Endocrinol (Paris), 2004;65:174–5.
ounta A, et al., Cholestatic liver injury after glimepiride therapy, J Hepatol, 2005;42:944–6.
lman KG, The liver and lovastatin, Am J Cardiol, 2002;89:1374–80.
w M, et al., Statin safety: a systematic review, Am J Cardiol, 2006;97:52C–60C.
143.Talbert RL, Safety issues with statin therapy, J Am Pharm Assoc, 2006;46:479–88; quiz 488–90.
hen DE, et al., An assessment of statin safety by hepatologists, Am J Cardiol, 2006;97:77C–81C.
la V, et al., Autoimmune hepatitis triggered by statins, J Clin Gastroenterol, 2006;40:757–61.
lli N, et al., Autoimmune hepatitis revealed by atorvastatin, Eur J Gastroenterol Hepatol, 2003;15:921–4.
147.Wolters LM, et al., Rosuvastatin-associated hepatitis with autoimmune features, Eur J Gastroenterol Hepatol, 2005;17:589–90.
aziadei IW, et al., Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis, Lupus, 2003;12:409–12.
orashadi S, et al., Incidence of statin hepatotoxicity in patients with hepatitis C, Clin Gastroenterol Hepatol, 2006;4:902– 7; quiz 806.
garra-Newnham M, et al., Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus, Pharmacotherapy, 2007;27:845–51.
151.Dujovne CA, Ettinger MP, McNeer JF, et al., Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia, Am J Cardiol, 2002;90:1092–7.
gne C, et al., Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia, Am J Cardiol, 2002;90:1084–91.
ndor A, et al., Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta- analysis of randomized controlled trials, J Intern Med, 2009;265:568–80.
olk MF, et al., Severe hepatic side effects of ezetimibe, Clin Gastroenterol Hepatol, 2006;4:908–11.
eff LB, Herbal hepatotoxicity, Clin Liver Dis, 2007;11:577–96, vii.
ssler RC, et al., Short screening scales to monitor population prevalences and trends in non-specific
psychological distress, Psychol Med, 2002;32:959–76.
ickel F, et al., Herbal hepatotoxicity, J Hepatol, 2005;43:901–10.
hoepfer AM, et al., Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products, J Hepatol, 2007;47:521–6.
ickel F, et al., Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis, J Hepatol, 2009;50:111–7.
160.Iwasa M, et al., pirulina-associated hepatotoxicity, Am J Gastroenterol, 2002;97:3212–3.
161.Favreau JT, et al., Severe hepatotoxicity associated with the dietary supplement LipoKinetix, Ann Intern Med, 2002;136:590–5.
tes JD, et al., High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure, Arch Surg, 2003;138:852–8.
oh S, et al., Liver injuries induced by herbal medicine, syo- saiko-to (xiao-chai-hu-tang), Dig Dis Sci, 1995;40:1845–8.
164.Hsu LM, et al., Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang, J Chin Med Assoc, 2006;69:86–8.
165.Kamiyama T, et al., Autoimmune hepatitis triggered by administration of an herbal medicine, Am J Gastroenterol, 1997;92:703–4.
166.Gordon DW, et al., Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications, JAMA, 1995;273:489–90.
167.Levy C, et al., Drug-induced cholestasis, Clin Liver Dis, 2003;7:311–30.
ickel F, et al., The efficacy and safety of comfrey, Public Health Nutr, 2000;3:501–8.
nninger J, et al., Acute hepatitis induced by greater celandine (Chelidonium majus), Gastroenterology, 1999;117:1234–7.
ickel F, et al., Acute hepatitis induced by Greater Celandine (Chelidonium majus), Scand J Gastroenterol, 2003;38:565–8.
ickel F, et al., Hepatitis induced by Kava (Piper methysticum rhizoma), J Hepatol, 2003;39:62–7.
dir A, et al., Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity, Am J Gastroenterol, 2000;95:3634–7.
stot A, et al., [Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance], Gastroenterol Clin Biol, 1992;16:916–22.
rrey D, et al., Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity, Ann Intern Med, 1992;117:129–32.
uwels A, Thierman-Duffaud D, Azanowsky JM, et al., [Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases], Gastroenterol Clin Biol, 1992;16:92–5.
ndaresan PR, et al., Isolation and characterisation of selected germander diterpenoids from authenticated Teucrium chamaedrys and T. canadense by HPLC, HPLC-mS and NMR, Phytochem Anal, 2006;17:243–50.
177.Woolf GM, et al., Acute hepatitis associated with the Chinese herbal product jin bu huan, Ann Intern Med, 1994;121:729–35.
178.Horowitz RS, et al., The clinical spectrum of Jin Bu Huan toxicity, Arch Intern Med, 1996;156:899–903.
179.Picciotto A, et al., Chronic hepatitis induced by Jin Bu Huan, J Hepatol, 1998;28:165–7.
dir A, et al., Acute hepatitis associated with the use of a Chinese herbal product, ma-huang, Am J Gastroenterol, 1996;91:1436–8.
rum ML, Fulminant exacerbation of autoimmune hepatitis after the use of ma huang, Am J Gastroenterol, 2001;96:1654–5.
ff GW, et al., Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid, J Hepatol, 2004;41:1062–4.
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92
| Page 93
| Page 94
| Page 95
| Page 96
| Page 97
| Page 98
| Page 99
| Page 100